Novo Nordisk announced on February 23, 2026, that its CagriSema treatment demonstrated a 23% weight loss after 84 weeks in a trial, though it did not meet its primary endpoint compared to tirzepatide, which had a 25.5% weight loss in the same timeframe. This trial included 809 participants with obesity and comorbidities, and further trials are planned to explore higher doses of CagriSema.